Trials / Unknown
UnknownNCT01900951
Temozolomide as Maintenance Therapy in Small Cell Lung Cancer
Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Temozolomide, a nonclassic oral alkylating agent, may delay progression in sequence with chemotherapy. This phase II trial was designed to evaluate the role of Temozolomide following 4 or 6 cycles of first-line treatment in patients with newly diagnosed SCLC.
Detailed description
Subjects will receive standard of care treatment for SCLC with added treatment of maintenance temozolomide. Efficacy and safety of temozolomide and one year survival and time to progression of patients will be recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temozolomide |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2016-02-01
- Completion
- 2016-06-01
- First posted
- 2013-07-17
- Last updated
- 2016-01-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01900951. Inclusion in this directory is not an endorsement.